Navigation Links
Biopure Receives Extension of Time to Regain NASDAQ Listing Compliance
Date:10/28/2008

CAMBRIDGE, Mass., Oct. 28 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has received notice from NASDAQ stating that the Company has until March 16, 2009, to regain compliance with Marketplace Rule 4310(c)(4), requiring a minimum bid price of $1.00 for continued listing. The deadline would have been December 8, 2008, but NASDAQ suspended enforcement of the minimum bid price requirement because of turmoil in the marketplace, thereby extending the Company's time in which to gain compliance.

Currently, the Company meets all other required inclusion criteria for the NASDAQ Capital Market. If, at any time before March 16, 2009, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will be provided written notification that it complies with the Marketplace Rule.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The Company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch.

Statements in this release that are not strictly historical are forward-looking statements, including any statements implying that the Company will be able to achieve the minimum bid price of $1.00 to avoid delisting from NASDAQ. Actual results and their timing may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, including its limited cash resources and need to raise additional capital to pursue its business, unexpected costs and expenses, delays and adverse determinations by regulatory authorities, unanticipated problems with the product's commercial use, whether or not product related, and with product distributors, sales agents or other third parties, delays in clinical trials, and the other factors identified under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q filed on June 16, 2008, as amended on June 18, 2008, which can be accessed in the EDGAR database at the U.S. Securities and Exchange Commission's (SEC) website, http://www.sec.gov. The company undertakes no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the SEC.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
9. DaVita Receives Civil Complaint
10. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to ... ability for patients to schedule an appointment online in real time,” said Keith English, ... Month Smiles provider directory will bring more Six Month Smiles patients to their providers.” ...
(Date:7/26/2017)... ... ... Musielak, a partner at the Andrew Cores Family Law Group, a division of ... this year. She will serve the membership in this capacity for a term of one ... organization’s by-laws. , Musielak joined the Andrew Cores Family Law Group ...
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service Group ... Regional Account Manager for the Northeast and Florida regions. In this role, Jennifer ... obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge and ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... in the United States, today announced its partnership with financial technology company, Automated ... The foundation of the solution lies within Hyosung’s superior ATMs, assisted self-service devices ...
(Date:7/24/2017)... COLLEGE PARK (PRWEB) , ... July 24, 2017 , ... ... It is bio-compatible, because it produces the same kind of electrical energy that the ... in the form of moving electrons. This flow of electrons out of the battery ...
Breaking Medicine News(10 mins):
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
(Date:7/6/2017)... the nutrition division of Diplomat Specialty Infusion Group, is celebrating a decade ... To celebrate its anniversary, ThriveRx recently launched a redesigned website at ... improved organization to create the best user experience for consumers and health ... Diplomat ... "We,ve made several great strides throughout the past ...
(Date:7/5/2017)... 5, 2017   BioLife Solutions , Inc. (NASDAQ: ... marketer of proprietary clinical grade cell and tissue ... ("BioLife"), today announced that it has reached an agreement ... largest shareholder, to modify its existing credit facility effective ... modification, WAVI agreed to exchange its existing $4.25 million ...
Breaking Medicine Technology: